Chemours vs Solstice Advanced Materials
CC and SOLS side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CC and SOLS compare
Solstice Advanced Materials is the larger company, worth 5.3 times as much as Chemours ($10.5B against $2.0B).
Solstice Advanced Materials grew revenue faster over the last twelve months (9.4% versus 0.07% for Chemours).
Solstice Advanced Materials keeps more of each dollar of sales as profit, with a net margin of 7.8% compared with −2.6% at Chemours.
Both pay dividends: Chemours yields 2.6% and Solstice Advanced Materials 0.34%.
Solstice Advanced Materials scores higher on the StockData Score (7 against 5 for Chemours), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CC | SOLS |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $10.5B |
| Share price | $13.29 | $66.12 |
| Change, 1 year | 5.4% | 40.9% |
| Change, 5 years | −58.1% | – |
| Beta (5Y) | 1.56 | – |
| Employees | 5,700 | 4,100 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 2 (better) | 1 |
| Valuation | ||
| P/E | – | 32.4× |
| P/S | 0.3× (better) | 2.5× |
| P/B | 12.9× | 6.7× (better) |
| EV/EBITDA | 7.1× | – |
| P/FCF | 9.5× (better) | 23.5× |
| FCF yield | 10.5% (better) | 4.2% |
| Fair value | – | $45.19 |
| Margin of safety | – | −46.3% |
| Growth | ||
| Revenue growth (TTM) | 0.07% | 9.4% (better) |
| Revenue growth, 5Y average | 3.2% | – |
| Net income growth (TTM) | – | −1.2% |
| Profitability | ||
| Gross margin | 15.2% | 30.9% (better) |
| Net margin | −2.6% | 7.8% (better) |
| FCF margin | 3.6% | 10.7% (better) |
| Return on equity | −71.8% | 13.6% (better) |
| Financial health | ||
| Debt / equity | 24.73 | 1.26 (better) |
| Net debt / EBITDA | 4.32 | – |
| Current ratio | 1.81 (better) | 1.38 |
| Altman Z-score | 1.41 | 2.30 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.6% (better) | 0.34% |
| Payout ratio | – | 473% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −12.5% | – |
| Shareholder yield | 2.6% (better) | 0.34% |
| Ownership | ||
| Held by institutions | 90.2% | 84.4% |
| Held by insiders | 0.96% | 0.04% |
| Insider net buying, 12 months | $489K | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.8% | 2.9% |
Go deeper
- CC stock overview
- CC income statement
- CC valuation and score
- SOLS stock overview
- SOLS income statement
- SOLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.